Financial reports
ARS
2023 FY
Annual report to shareholders
22 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
1 May 23
ARS
2022 FY
Annual report to shareholders
16 Mar 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Redemption Date Announced for Warrants
15 Apr 24
8-K
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
28 Feb 24
8-K
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
7 Feb 24
8-K
Entry into a Material Definitive Agreement
3 Jan 24
8-K
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
12 Dec 23
8-K
Cassava Sciences Appoints
11 Dec 23
8-K
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
7 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
13 Sep 23
8-K
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
3 Aug 23
8-K
Other Events
5 Jul 23
Registration and prospectus
424B2
Prospectus for primary offering
3 Jan 24
8-A12B
Registration of securities on exchange
3 Jan 24
8-A12G
Registration of securities
2 Jan 24
424B5
Prospectus supplement for primary offering
1 May 23
S-3ASR
Automatic shelf registration
1 May 23
424B5
Prospectus supplement for primary offering
21 Nov 22
424B5
Prospectus supplement for primary offering
29 Jul 22
S-8
Registration of securities for employees
10 Jun 22
424B5
Prospectus supplement for primary offering
12 Feb 21
S-3ASR
Automatic shelf registration
10 Feb 21
Proxies
DEF 14A
Definitive proxy
26 Mar 24
DEF 14A
Definitive proxy
27 Mar 23
PRE 14A
Preliminary proxy
16 Mar 23
DEF 14A
Definitive proxy
24 Mar 22
DEF 14A
Definitive proxy
31 Mar 21
DEF 14A
Definitive proxy
26 Mar 20
DEF 14A
Definitive proxy
29 Mar 19
DEF 14A
Definitive proxy
27 Mar 18
PRE 14A
Preliminary proxy
16 Mar 18
DEFA14A
Additional proxy soliciting materials
29 Mar 17
Other
CERT
Certification of approval for exchange listing
3 Jan 24
UPLOAD
Letter from SEC
14 Aug 23
CORRESP
Correspondence with SEC
10 Aug 23
UPLOAD
Letter from SEC
28 Jul 23
EFFECT
Notice of effectiveness
6 May 20
CORRESP
Correspondence with SEC
1 May 20
CORRESP
Correspondence with SEC
9 Apr 20
UPLOAD
Letter from SEC
2 Apr 20
EFFECT
Notice of effectiveness
31 Jan 19
CORRESP
Correspondence with SEC
28 Jan 19
Ownership
4
Eric Schoen
17 Apr 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BARBIER REMI
1 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Claude Nicaise
8 Dec 23
3
Claude Nicaise
8 Dec 23
4
Pierre Gravier
7 Dec 23
4
Robert Eugene Anderson Jr
7 Dec 23
3
Pierre Gravier
7 Dec 23
3
Robert Eugene Anderson Jr
7 Dec 23